CSPC. Group is one of the leading comprehensive pharmaceutical companies in China, with product pipeline in innovative drugs and professional product marketing ability, who has synergy with I-Mab Biopharma’s development areas. Parties are willing to carry out strategic cooperation on TG103 products, and develop and commercialize TG103 products for the treatment of type 2 diabetes mellitus and all indications related to this product in the territory. THEREFORE, the parties have reached the following agreements, which shall be abided by both parties.
Appears in 2 contracts
Sources: Product Development Agreement (I-Mab), Product Development Agreement (I-Mab)